Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor and is among the deadliest of human cancers. Despite advances in diagnosis and treatment, mean survival times are around 12-15 months. These tumors typically have a very high proliferative rate with widespread microvascular proliferation and areas of focal necrosis. They develop stepwise accumulation of multiple genetic alterations, which result in the activation of oncogenes and/or the inactivation of tumor-suppressor genes. Major pathways are frequently dysregulated including PI3 kinase/ AKT/mTOR/PTEN, [1] [2] [3] p16 (INK4A)-cyclin-dependent kinase 4 (CDK4)/6-pRb 4, 5 and p14 (ARF)-MDM2/4-p53. 6 Almost all GBM samples (91%) have an abnormality of at least one of these three pathways. 7 Additionally, microarray studies revealed that expression of hundreds of gene transcripts are altered in gliomas compared with normal brain tissue. 8 The microRNAs (miRNAs) are small noncoding RNAs that have critical roles in regulating a number of cellular functions through post-transcriptional silencing in mammalian cells. A global decrease in miRNA levels is often observed in human cancers, suggesting that miRNAs may function as tumor suppressors. 9 miR-34 is one of the tumor suppressor miRNA families, which includes miR-34a, miR-34b and miR-34c. Welch et al. reported that miR-34a induced apoptosis when reintroduced into a neuroblatoma cell line, 10 and also miR-34a was identified as a p53 target. 11, 12 The expression level of miR-34a is associated with the genomic integrity of both miR-34a and p53. 12, 13 The known targets of miR-34a include CDK4/6, cyclin E, Met, Myc and Bcl-2. 12, 14 In this study, we use single-nucleotide polymorphism DNA microarray (SNP-Chip, Affymetrix, Santa Clara, CA, USA) and found that 17 of the 55 GBM samples had hemizygous miR-34a, and 2 others had a homozygous deletion of miR-34a (total 19/55, 35%). Also, 35 of the 55 GBM samples (66%) had an amplification of epidermal growth factor receptor (EGFR) (18 samples with lowlevel copy number amplification (trisomy), and 17 samples with high-level copy number amplifications). We found for the first time that survival of GBM patients was significantly shortened if their GBM had both EGFR amplification and miR-34a deletion. Forced expression of miR-34a in GBM cell lines downregulated EGFR mediated by Yin Yang-1 (YY1), as well as inhibited their growth both in vitro and in vivo associated with a profound decreased expression of key cell cycle regulatory proteins.
RESULTS
Genomic deletion of miR-34a and amplification of EGFR is associated with overall decreased survival of patients with GBM High resolution whole genomic copy number profiling of 55 samples was analyzed using SNP-Chip array. 7 Deletion of miR-34a occurred in 19 samples (35%) including 2 samples with a homozygous deletion (T32, T6) ( Figure 1a) ; and the amplification of EGFR occurred in 35 of the 55 GBM samples (66%) (18 with low level copy number amplification (3 or 4 copies of EGFR), and 17 with high level copy number amplifications (more than 4 copies of EGFR) (Figure 1b) . Twelve of the 55 GBM samples (18%) had both EGFR amplification (including both low and high copy number amplification) and miR-34a deletion (Figure 1b and c; Supplementary Table 1) . The mean survival time was significantly shortened (Po0.05) in the patients whose GBM had both EGFR amplification and miR-34a deletion compared to those with normal copy number of both of EGFR and miR-34a, or with either amplification of EGFR or deletion of miR-34a (Figure 1d ). Expression of the mature miR-34a from 5 normal brain samples and 26 GBM samples was measured using real-time RT-PCR. Twenty of the 26 (77%) GBM samples had greater than 50% decreased levels of miR-34a compared with levels in the normal brain (Figure 1e ), and the expression of miR-34a was significantly less in GBM samples than in normal brains (t-test, Po0.05) (Supplementary Figure 1A) . miR-34a levels were higher in samples with normal status of miR-34a and p53 compared with samples with deleted miR-34a and abnormal p53 (t-test, Po0.05) (Figure 1f ). The expression of mature miR-34a in six GBM cell lines (U87, U251, U138, U343, U373 and T98G) was also examined by real-time PCR. U87 cells with wild-type p53 had the highest expression of miR34a compared with the five other p53 mutant GBM cell lines (Supplementary Figure 1B) . We also found that tumor samples with high expression of miR-34a always had lower expression of EGFR and YY1 than those samples with low expression of mir-34a (Supplementary Figure 1E) . miR-34a inhibits GBM cell growth and migration in vitro GBM cell lines were stably infected using a retrovirus expressing miR-34a gene (Materials and methods) resulting in a significantly increased expression of mature miR-34a (Figure 2a) . Proliferation of cells with overexpression of miR-34a decreased as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Figure 2b ) and by clonogenic assay (Figure 2c ). Furthermore, these miR-34a-overexpressing GBM cells had more than sixfold decreased migration as measured using a Boyden chamber (Figure 2d ). G0-G1 cell cycle arrest and apoptosis also occurred in cells stably expressing mir-34a (Figure 2e and f). miR-34a markedly modulates expression of cell cycle proteins and EGFR in glioma cells Cyclin-A1, -D1, -D3, as well as CDK2, E2F-1, -3 and -4 were downregulated, and the cyclin kinase inhibitors p27 were up-regulated in the GBM cell lines U251 and T98G after they were engineered stably to express miR-34a (Figure 3a) . The expression of EGFR was profoundly decreased in these GBM cells (Figure 3b ). They also had decreased levels of the known EGFR downstream targets: activated p-AKT and p-ERK (Figure 3b) . Furthermore, antisense oligo against mature miR-34a was transfected into U87; these cells were chosen because they had higher endogenous miR-34a expression compared to the other 5 GBM cell lines (Supplementary Figure 1B) . The protein expression of EGFR, p-AKT and p-ERK increased in these antisense oligo transfected cells, but not in those transfected with scrambled oligo (Figure 3c ). In addition, the EGFR expression vector was transfected into U251-C, U251-34a, T98G-C and T98G-34a cells. Forced expression of EGFR reversed the growth inhibition of the U251-34a and T98G-34a cells ( Supplementary Figures 2A and B) .
To determine if our observation concerning miR-34a was limited to GBM, we examined the effect of miR-34a on expression of cell cycle proteins and EGFR in a skin cancer (A341) and a breast cancer (MDA-MB-231) cell lines. Similar to GBM, miR-34a markedly decreased EGFR, as well as E2F-1, -3, -4 and p-ERK, and increased cyclin kinase inhibitors p21 in these cells (Figure 3d ). miR-34a lowers expression of EGFR in part through YY1 In order to explore how miR-34a modulates the expression of EGFR, three databases (TargetScan (http://www.targetscan.org), PicTar (http://pictar.mdc-berlin.de) and miRanda (http://www. microrna.org)) were interrogated to determine if the 3 0 -UTR of EGFR was a target of miR-34a. None of them strongly identified EGFR as a target of miR-34a. In additional experiments, we found that the luciferase activity decreased 40% using a reporter construct containing the full length 3 0 -UTR of EGFR (Supplementary Figure 2C) . However, no clear conserved seed sequence of miR-34a was identified in 3 0 -UTR of EGFR using the above three data bases. We did mutate two degenerate miR-34a binding sites in the 3 0 -UTR of EGFR and repeated the luciferase assay. However, only 10% reversal of luciferase activity occurred (data not shown), suggesting that EGFR mRNA was not a direct target of miR-34a.
Interestingly, YY1, which is a transcription factor increasing expression of EGFR, 15 was identified as a target of miR-34a by all the three databases. We co-transfected miR-34a expression vector with a vector containing the 3 0 -UTR of YY1 attached to the luciferase gene, and found that miR-34a decreased luciferase activity by 40% in both U251 and T98G GBM cell lines. No decrease of activity occurred when a mutant 3 0 -UTR replaced the wild type 3 0 -UTR of YY1 (Supplementary Figure 2D) . Therefore, we hypothesized that miR-34a regulated EGFR expression through regulation of YY1. A luciferase reporter construct with the promoter of EGFR was transfected into U251 and T98G GBM cells with either miR-34a or control vector. Luciferase activity decreased about 50% in cells infected with miR-34a compared with vector control cells, and the luciferase signal recovered when YY1 expression vector was co-transfected in both of these GBM cell lines (Figure 4a) . In further experiments, we found that protein expression of EGFR decreased in U251 and T98G cells transfected with a miR-34a expression vector, and rebounded in these GBM cells that were transfected with both (c) Measurement of DNA allelic copy number using quantitative PCR on GBM samples having both a miR-34a deletion and an EGFR amplification (normal DNA is 2N). (d) KaplanMeier estimates of overall survival for patients whose GBM have EGFR amplification and miR-34a deletion; EGFR wild type and miR-34a wild type; EGFR amplification but miR-34a wild type; EGFR wild type but miR-34a deletion. (e) Expression of miR-34a in normal brain and GBM samples measured by real-time RT-PCR. Mean expression levels of miR-34a in 5 normal brain samples were normalized to 100. The dotted line indicates half of the mean level present in normal brain tissue. Symbols: (w/w), wild type of both miR-34a and p53; (-/-), miR-34a deletion and abnormal p53; (-/w), miR-34a deletion but p53 wild type; (w/-), miR-34a wild type but abnormal p53. (f ) Expression of miR-34a in GBM samples with wild type of both miR-34a and p53 (w/w) compared with GBM samples with miR-34a deletion and/or abnormal p53. The solid line indicates the medium expression level of each group. miR-34a and YY1 expression vectors (Figure 4b ). We also found that overexpression of YY1 reversed the G0-G1 cell cycle arrest caused by mir-34a (Supplementary Figure 2E) . In addition, siRNA against YY1 transfected into U251 and T98G decreased the expression of YY1, as well as EGFR (Figure 4c ; Supplementary Figure 2F ).
miR-34a inhibits growth of GBM cells in vivo
The U251 GBM cells (having nearly undetectable levels of miR-34a (Supplementary Figure 1B) ) were stably infected with either the miR-34a expression vector or control vector. These cells were injected subcutaneously into immunodeficient mice.
miR-34a functions as a tumor suppressor modulating EGFR in GBM D Yin et al.
miR-34a functions as a tumor suppressor modulating EGFR in GBM D Yin et al.
The rate of growth of tumors derived from U251-control cells was much faster compared with tumors expressing miR-34a (Po0.01) (Figure 5a ). Tumors were removed in 32 days. Those expressing miR-34a were significantly smaller (Po0.01, Figure 5b ), and had less expression of EGFR, YY1 and E2F3 than the control cells (Figure 5c ), less vascularity (as shown by CD31 staining, Figure 5d ) and expressed much lower levels of EGFR compared with the tumors derived from control vector containing GBM cells (Figure 5e ).
DISCUSSION
The miR-34 family includes three microRNAs, miR-34a, miR-34b and miR-34c. miR-34a is located at 1p36 and this chromosomal region is deleted in various types of tumors including gliomas. two GBM samples with a small homozygous deletion localized at miR-34a (1p36.23), which only contained two other genes GPR157 and H6PD. A homozygous deletion is usually a giant stone marking the loss of an important tumor-suppressor gene associated with cancer. Of interest, both miR-34b and miR-34c are located at 11q22.3-23.3, and also have been reported to be tumor suppressors. 32, 33 We found heterozygous deletions at 11q22.3-23.3 (Supplementary Table 1 ). We did not pursue further studies of these two micro RNAs.
In total, we found that 19 of the 55 (35%) GBM samples had either a hemi-or homozygous deletion of miR-34a. Real-time RT-PCR revealed that the expression of miR-34a was lower in GBM samples compared with normal brain tissue. Prior studies have clearly shown that an activated wild-type p53 protein can induce expression of miR-34a. 11, 12 A p53 binding site is located within the miR-34a, and forced expression of p53 can induce expression of miR-34a. 26, 34 Consistent with these reports, we also found that the GBM cell line with a wild-type p53 (U87) had the highest expression of miR-34a compared with the other five GBM cell lines harboring a mutant p53. Mutation or deletion of p53 occurred in 35% of our GBM samples, which can also contribute to the downregulation of miR-34a in GBM. In addition, miR-34a can also be silenced by aberrant CpG methylation of its promoter region as reported for several other types of cancers. 35 This study found that downregulation of miR-34a was associated with the deletion of chromosome 1p36.32 and with p53 abnormalities (deletion, AUPD and mutation) (Po0.05, Figure 1f) . miR-34a has been reported to have antitumor activity in various cancers, 10, 13, 23, 26, 29, 36 associated with G1 cell cycle arrest. 13, 14, 23, 36 We found that both proliferation and migration of GBM cells were significantly decreased after forced expression of miR-34a in GBM cells. This was associated with reduced levels of Cyclin-A1, -D1, -D3, CDK2, E2F-1, -4, -3, and increased expression of the p21 and p27 CDKIs. All of these changes in protein expression are consistent with a profound antiproliferative activity of miR-34a. To our knowledge, this is the first report that the survival times were significantly shortened for patients whose GBM had both EGFR amplification and miR-34a deletion. We also analyzed the survival of 188 GBM individuals (The Cancer Genome Atlas (TCGA) project data 37 ). Patients with both miR-34a deletion and EGFR amplification had a significantly worse survival compared with those with no deletion of miR-34a and no amplification of EGFR (Supplementary Figure 3) .
Wild-type p53 normally enhances the levels of miR-34a. As expected, we found that either loss of a functional p53 or deletion of miR-34a was associated with downregulation of miR-34a in GBM (Figure 1f ). Forced expression of miR-34a, markedly decreased the level of EGFR in GBM cells (Figure 3b) . Increasing the protein level of EGFR as a result of loss of miR-34a (Figure 3c ) likely provides a growth advantage to these GBM cells. The ability of miR-34a to decrease EGFR was not limited to GBM cells, but was also detected in skin cancer (A341) and breast cancer (MDA-MB-231) cell lines (Figure 3d ). Tangential to our investigation, a prior study noted that the elevated levels of EGFR occurred in GBMs containing a mutant p53. 38 Recent studies reported that YY1 is one of the targets of miR34a, 39, 40 and loss of p53 induces EGFR promoter activity via YY1. 15 Therefore, we hypothesize that mir-34a downregulates EGFR through YY1. Our results suggest that this hypothesis is correct. First, YY1 was identified as a target of mir-34a; second, miR-34a decreased the expression and promoter activity of EGFR; third, overexpression of YY1 reversed the suppression of EGFR caused by miR-34a. In addition, luciferase reporter analysis indicated that miR-34a affected EGFR though its 3'-UTR, but direct binding seed sequence was not identified. To illustrate our findings, we proposed a simplified model of mechanism by which EGFR is modulated by the p53-miR-34a-YY1 pathway (Figure 4d ). To support our in vitro results, a human GBM xenograft tumor model was developed using immunodeficient mice. GBM xenografts with forced expression of miR-34a grew significantly slower and had lower expression of EGFR and less vascularity compared with the control xenografts without miR-34a.
In summary, we found that 35% of gliomas had a deletion of the miR-34a gene at 1p36.23, and the expression of the mature miR-34a was markedly decreased in clinical GBM samples compared with normal brain tissue. Forced expression of miR34a in GBM cells inhibited their in vitro and/or in vivo ability to migrate and to grow in association with decreased angiogenesis. miR-34a decreased the expression of EGFR through YY1, as well as lowered the levels of proteins involved in stimulating cell proliferation. Taken together, our findings suggest that deletion of miR-34a and amplification of EGFR in GBM at diagnosis often foretells a poor prognosis, and elevating levels of miR-34a should be considered a potential therapeutic approach for GBM even in the absence of a functional p53 gene. 
MATERIALS AND METHODS

Clinical samples and cell lines
GBM from 55 individuals and six human GBM cell lines (U87, U251, U138, U343, U373 and T98G) were used in this study. GBM cell lines and their various clones were maintained in Dulbecco's modified Eagle's medium (Gibco, BRL) with 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA), 10 U/ml penicillin-G, and 10 mg/ml streptomycin (Gemini BioProducts). All cells were incubated at 37 o C in 5% CO 2 .
DNA preparation and high-density SNP-chip analysis K-phenol-chloroform extraction method was used to extract DNA from GBM samples and cell lines. Written informed consent for research use of all of these samples was obtained before surgery, according to a protocol approved by the institutional ethics committee. SNP-chips for human 50 k XbaI/ 250 k Nsp arrays were used for this study (SNP-chip) as previous described. 7, 41, 42 All the raw data of these SNP-Chips have been submitted to the public database ArrayExpress (http://www.ebi.ac.uk/microarray-as/ ae/), ArrayExpress accession number is E-MEXP-1330.
Real-time RT-PCR
Total RNA was extracted using miRNAeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. RNA was reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA. USA). To measure miR-34a, real-time PCR was performed using TaqMan MicroRNA Assay (Hsa-miR-34a) Kit, and RNU48 as an internal control. PCR conditions followed the manufacturer's protocol using an iCycler iQ system (Bio-Rad, Hercules, CA, USA). The relative expression level of miR-34a in normal control samples was normalized to a relative value of 1. Final results in treated samples were expressed as N-fold differences to the control samples.
Retroviral expression of miR-34a
Retroviral vector pMSCV-PIG 43 containing miR-34a and approximately 100 bp of flanking sequences was kindly provided by Dr Mendel. 11 The control retroviral vector was constructed by removal of the miR-34a mature sequence using Quick Change Kit (Stratagene, La Jolla, CA, USA). Following transfection of Phoenix packaging cells (G. Nolan, Stanford University, Stanford, CA, USA), retroviral supernatants were collected, filtered and added to recipient cells for 8 h in the presence of 8 mg/ml polybrene. Two days after infection, puromycin (1 mg/ml) was added to the media, and cells were selected for 2 weeks.
Assay of clonogenic growth and cell proliferation in vitro GBM cells were infected with either pMSCV-PIG-34a or pMSCV-PIG-control. Puromycin-selected infected cells were placed into 12-wells dishes (1000 cells/well). After 2 weeks in culture medium, the colonies were stained with crystal violet, solubilized with 10% acetic acid, and the optical density of the extracts was measured by a spectrophotometer at OD600. Infected cells were placed into 96-well plates at 1000 cells/well. Cell numbers were measured by MTT assay according to the protocol provided by Roche Molecular Biochemicals (Basel, Switzerland).
Cell migration assays
Cell migration assays were performed using a Boyden chamber (10 mm thickness and 8 mm pores) containing polycarbonate membranes (6.5 mm diameter). Cells were allowed to migrate to the underside of the top chamber for 8 h. The migratory cells attached to the bottom surface of the membrane were stained with 0.1% crystal violet in 0.1 M borate, pH 9.0 and 2% ethanol for 20 min at room temperature. The stained cells were counted microscopically.
Western blot analysis
Western blot was performed as previously described. 44 p-AKT antibody was from Cell Signaling (Danvers, MA, USA). All other antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Luciferase assays
Luciferase reporter construct with the 3 0 -UTR of EGFR (Luc-3 0 -UTR-EGFR) was generously provided by Dr Purow. 45 EGFR promoter reporter vector was constructed by cloning EGFR promoter in front of the luciferase gene (Luc-promoter-EGFR). Wild-type or mutant 3 0 -UTR of YY1 luciferase reporter vector (Luc-3 0 -UTR-YY1) was generously provided by Dr Khan 40 . One day before transfection, 5 Â 10 4 cells/well were plated in a 24-well plate. After 24 h, 400 ng Luc reporter vectors plus 4 ng of the Renilla luciferase plasmid phRL-SV40 (Promega, Madison, WI, USA) were co-transfected with other relevant vectors. After an additional 24 h, luciferase assays were performed using the dual luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected well. For each experimental trial, wells were transfected in triplicate.
Inhibition of miR-34a expression U87 cells which have high miR-34a expression (compared with other GBM cell lines), were transfected with either scrambled oligo (as control) or antisense oligo (ACAACCAGCUAAGACACUGCCA) of mature miR-34a.
in vivo tumor studies Human GBM, U251-34a and U251-control cells (2 Â 10 6 ) were injected s.c. into an 8-week-old Beige Nude XID (BNX, NIH III from Harlan Laboratories) mice, and tumor growth was measured weekly. Tumors were analyzed immunohistochemically for angiogenesis using monoclonal antibodies against CD31 and EGFR.
Immunohistochemistry for CD31 and EGFR
Tumors that developed from U251-34a and U251-control GBM cells growing in BNX nude mice were dissected and examined for expression of CD31 and EGFR using immunohistochemistry as previous described. 44 Monoclonal antibody to CD31 (Dako Corporation, Carpinteria, CA, USA) and EGFR (Santa Cruz Biotechnology Inc.) were applied at a dilution of 1:400 for 45 min at room temperature. The sections were counterstained with hematoxylin.
Statistical analysis
Differences between the results of experimental treatments were evaluated by the t-test. Overall survival was analyzed with the KaplanMeier method to assess prognostic significance of the observed genomic abnormalities. We applied the log rank test to compare patients either with or without a specific genomic abnormality. Differences were considered significant at values of Po0.05.
